Semax.

Semax is a research compound in the cognitive neuropeptides.

Its biological effect is described in the mechanism section.

It draws interest for cognitive neuropeptides.

D-tier evidence: human evidence is limited; most support is preclinical.

What it is

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment of adrenocorticotropic hormone joined to a C-terminal Pro-Gly-Pro tripeptide. It was developed in the late 1980s/early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and is first described in the scientific literature around 1991. The Pro-Gly-Pro extension stabilizes the otherwise rapidly degraded ACTH fragment without retaining ACTH's hormonal (corticosteroid-releasing) activity, making Semax a "neuropeptide" rather than a hormone.

How it works

Semax is structurally derived from ACTH(4-10) but lacks the melanocortin-receptor-driven hormonal effects of full-length ACTH, so it does not stimulate cortisol release. Mechanistic (largely rodent and in vitro) work indicates it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, and modulates expression of NGF and other neurotrophic and immune-response genes, which is proposed to support neuronal survival and synaptic plasticity. A separate biochemical mechanism is inhibition of enkephalin-degrading enzymes in human serum (reported IC50 ~10 µM), which may prolong the activity of endogenous regulatory peptides. The relative contribution of each pathway to any observed clinical effect remains unsettled; Wikipedia and reviews note the precise mechanism of action is not definitively established.

What the evidence shows

Human evidence comes almost entirely from Russian clinical research and is modest in scale. A representative controlled study by Gusev, Martynov and colleagues (Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983) in 110 ischemic-stroke patients reported that semax plus early rehabilitation raised plasma BDNF and improved motor recovery and functional independence (Barthel index). The strongest mechanistic data—BDNF/TrkB upregulation (Brain Research, 2006; PMID 16996037), neuroprotection and immune-gene regulation in rat ischemia (Mol Genet Genomics, 2017; PMID 28255762)—are preclinical (rat/in vitro). Proposed uses such as ADHD or cognitive enhancement rest largely on hypothesis papers (e.g., Med Hypotheses, 2007; PMID 16996699) rather than rigorous trials. Crucially, no large, independent, randomized, double-blind Western trials have replicated the Russian findings, so the human cognitive- and stroke-benefit claims should be regarded as preliminary.

Safety considerations

Russian clinical reports and the intranasal route describe generally good tolerability, with mild nasal/local irritation the most commonly noted complaint; however, these data come from small studies without the long-term, independent safety surveillance expected for Western drug approval. There is no robust characterization of long-term safety, drug interactions, effects in pregnancy, or risks from non-pharmaceutical "research-use" material sold online, which may vary in purity and sterility. Because much of the mechanistic profile (BDNF/neurotrophin modulation, peptidase inhibition) is extrapolated from animal models, downstream effects of chronic human use are essentially unstudied. Product sold by online vendors is not manufactured to pharmaceutical standards and its identity and contaminants are not guaranteed.

Regulatory status

Semax is approved as a prescription drug in Russia (and appears on Russia's List of Vital and Essential Drugs) for indications including ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved and is unscheduled in the United States, where it is sold by online vendors as a research/non-pharmaceutical product; it is not approved or marketed in most countries outside Russia.

1. [1]The efficacy of semax in the treatment of patients at different stages of ischemic stroke — Gusev EI, Martynov MYu, et al. Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983
2. [2]Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Brain Research, 2006; PMID 16996037
3. [3]Semax and Selank inhibit the enkephalin-degrading enzymes of human serum — Russian Journal of Bioorganic Chemistry, 2001; PMID 11443939
4. [4]Semax (overview, sequence, and regulatory status) — Wikipedia, accessed 2026

• Not FDA-approved; research-only in most countries.
• Long-term safety and nootropic benefit in healthy adults are not established.

Stack fit

Why not C: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

Why not F: supported by its overall evidence profile.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Semax is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Cognitive neuropeptides class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The preclinical evidence lane
3. Why Early, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently